Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Net Cash Flow (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Net Cash Flow for 15 consecutive years, with -$15.4 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 61.79% to -$15.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.3 million through Dec 2025, up 47.25% year-over-year, with the annual reading at -$52.0 million for FY2025, 150.75% down from the prior year.
  • Net Cash Flow hit -$15.4 million in Q4 2025 for Vistagen Therapeutics, down from $13.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $89.0 million in Q4 2023 to a low of -$18.7 million in Q3 2024.
  • Historically, Net Cash Flow has averaged -$3.1 million across 5 years, with a median of -$9.5 million in 2021.
  • Biggest five-year swings in Net Cash Flow: plummeted 2894.23% in 2021 and later surged 967.83% in 2023.
  • Year by year, Net Cash Flow stood at -$9.9 million in 2021, then fell by 3.25% to -$10.2 million in 2022, then soared by 967.83% to $89.0 million in 2023, then tumbled by 110.71% to -$9.5 million in 2024, then tumbled by 61.79% to -$15.4 million in 2025.
  • Business Quant data shows Net Cash Flow for VTGN at -$15.4 million in Q4 2025, $13.8 million in Q3 2025, and -$18.1 million in Q2 2025.